<DOC>
	<DOCNO>NCT01232127</DOCNO>
	<brief_summary>The purpose study assess effect famotidine , give twice daily , atazanavir administer ritonavir tenofovir HIV-infected participant .</brief_summary>
	<brief_title>Effects Famotidine Pharmacokinetics Atazanavir When Coadministered Participants With HIV Infection</brief_title>
	<detailed_description>This protocol design compare pharmacokinetic parameter atazanavir administer atazanavir/ritonavir , 400/100 mg daily ( QD ) , plus famotidine , 20 mg 40 mg twice daily , parameter find usual clinical dose atazanavir/ritonavir , 300/100 mg QD , without famotidine HIV-infected participant receive tenofovir disoproxil fumarate least 1 nucleoside reverse transcriptase inhibitor .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Key inclusion criterion : Males female , 18 65 year age , HIV infection body mass index 18.0 35.0 kg/m^2 HIVinfected participant receive treatment regimen contain atazanavir/ritonavir , 300/100 mg daily ( QD ) + tenofovir , 300 mg QD + least 1 nucleotide reverse transcriptase inhibitor continuously least 3 month prior study day 1 Plasma HIV RNA level &lt; 50 copies/mL CD4 count &gt; 200 cells/mm^3 . No history virologic failure protease inhibitor ( PI ) , document phenotypic PI resistance , primary PI mutation , accord International AIDS Society recommendations No document phenotypic resistance atazanavir primary genotypic mutation cause resistance atazanavir Women childbearing potential nursing pregnant use acceptable method contraception least 4 week dose , study , 8 week last dose study drug . Women negative pregnancy test result within 24 hour prior dose study medication Women breastfeed Men willing able agree practice barrier contraception duration study least 3 month dose . Key exclusion criterion : Any history CD4 cell count &lt; 50 cells/mm^3 Previously document phenotypic genotypic resistance currently prescribe NRTIs Any significant acute illness within 6 month study day 1 chronic medical illness unless stable control nonprohibited medication Any major surgery within 4 week study day 1 Any gastrointestinal surgery could impact upon absorption study drug Inability venipunctured and/or tolerate venous access History Gilbert 's syndrome , hemophilia , chronic pancreatitis , hypochlorhydria , achlorhydria , clinically relevant gastroesophageal reflux disease , hiatal hernia , peptic/gastric ulcer disease Intractable diarrhea ( ≥ 6 loose stools/day least 7 consecutive day ) within 30 day prior study day 1 Recent ( within 6 month prior study day 1 ) drug alcohol abuse Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , electrocardiogram ( ECG ) Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG , clinical laboratory determination , would expect extent HIV disease Any follow 12lead ECG prior dose study day 1 , confirm repeat : PR ≥ 210 msec ; QRS ≥ 120 msec ; QT ≥ 500 msec ; QTcF ≥ 450 msec Second thirddegree AV block clinically relevant ECG abnormality Positive urine screen drug abuse screen prior dose without valid prescription . Positive urine drug screen cannabinoids without prescription exclusionary Creatinine clearance , estimate method Cockcroft Gault , less 60 mL/min Liver enzyme level &gt; 3* upper limit normal ( ULN ) prior dose study day 1 Total bilirubin level &gt; 10*ULN prior study day 1 Positive blood screen hepatitis B surface antigen hepatitis C antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>